|Bid||35.11 x 900|
|Ask||35.14 x 800|
|Day's Range||35.00 - 36.53|
|52 Week Range||27.70 - 48.28|
|Beta (5Y Monthly)||0.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.00|
Increase in vaccinations and simultaneous decrease in COVID-19 hospitalizations in February and March result in improved procedure volumes for Cardiovascular Systems (CSII) in Q3.
With me today are Scott Ward, CSI Chairman, President and Chief Executive Officer; Rhonda Robb, Chief Operating Officer; Jeff Points, Chief Financial Officer; and Dr. Ryan Egeland, Chief Medical Officer. Approximately 30 minutes ago, we issued a press release announcing third quarter results.
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -50.00% and -0.25%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?